A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
Study of Glutaminase Inhibitor CB-839 HCl in Subjects with Advanced Solid Tumors
Sponsor: National Cancer Institute NCI NIH DHHS
Enrolling: Male and Female Patients
IRB Number: AAAS6875
U.S. Govt. ID: NCT03872427
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the good and bad effects of the drug called CB-839 HCl (telaglenastat). CB-839 HCl (telaglenastat) could shrink your cancer, but it could also cause side effects. The study doctors hope to learn if the study drug will help control the disease in patients with advanced cancer with changes in specific genes. We don't know if CB-839 HCl works to treat cancer in people, but it has shrunk several types of tumors in animals. There will be about 108 people taking part in this study.
This study is closed
Investigator
Gary Schwartz, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a metastatic or unresectable advanced solid tumor with NF1 mutation? Yes No
Has it been 4 weeks from your last surgery or radiation therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162